Advertisement
U.S. markets open in 5 hours 11 minutes
  • S&P Futures

    5,304.25
    -4.00 (-0.08%)
     
  • Dow Futures

    40,102.00
    -42.00 (-0.10%)
     
  • Nasdaq Futures

    18,493.75
    -10.00 (-0.05%)
     
  • Russell 2000 Futures

    2,134.60
    -3.80 (-0.18%)
     
  • Crude Oil

    81.77
    +0.42 (+0.52%)
     
  • Gold

    2,213.10
    +0.40 (+0.02%)
     
  • Silver

    24.56
    -0.20 (-0.80%)
     
  • EUR/USD

    1.0793
    -0.0036 (-0.33%)
     
  • 10-Yr Bond

    4.1960
    0.0000 (0.00%)
     
  • Vix

    12.94
    +0.16 (+1.25%)
     
  • GBP/USD

    1.2607
    -0.0031 (-0.25%)
     
  • USD/JPY

    151.3780
    +0.1320 (+0.09%)
     
  • Bitcoin USD

    70,410.75
    +466.34 (+0.67%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,953.48
    +21.50 (+0.27%)
     
  • Nikkei 225

    40,168.07
    -594.66 (-1.46%)
     

Treating Bipolar 1 Disorder

Healthcare professionals share perspectives on providing care for people living with bipolar 1 disorder

Northampton, MA --News Direct-- Alkermes

Check out a new infographic with findings from our latest survey conducted in partnership with The Harris Poll and Depression and Bipolar Support Alliance – National Headquarters. Learn what healthcare providers (HCPs) had to say about treating individuals with bipolar 1 disorder: https://bit.ly/383gMvq

About AlkermesAlkermes plc is a fully-integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology. The company has a portfolio of proprietary commercial products focused on alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurodegenerative disorders and cancer. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. For more information, please visit Alkermes' website at www.alkermes.com.

View additional multimedia and more ESG storytelling from Alkermes on 3blmedia.com

View source version on newsdirect.com: https://newsdirect.com/news/treating-bipolar-1-disorder-246486034

Advertisement